Sclerostin and DKK1: New players in renal bone and vascular disease

Kidney International

Volumn 88, Issue 2, 2015, Pages 235-240

  Evenepoel, Pieter ^a   D'Haese, Patrick ^b   Brandenburg, Vincent ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

bone; cardiovascular disease; DKK1; mineral metabolism; sclerostin

Indexed keywords

DICKKOPF 1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; GENETIC MARKER; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ARTICLE; BONE DENSITY; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; INTERNALIZATION; LOSS OF FUNCTION MUTATION; MINERALIZATION; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; RENOVASCULAR DISEASE; SEASONAL VARIATION; SIGNAL TRANSDUCTION; BLOOD; BONE DEVELOPMENT; BONE DISEASE; CALCINOSIS; CHRONIC KIDNEY FAILURE; GENETIC MARKER; OSTEOLYSIS; VASCULAR DISEASE; WNT SIGNALING PATHWAY;

BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; CALCINOSIS; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOGENESIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES; WNT SIGNALING PATHWAY;

EID: 84938555950     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.156     Document Type: Short Survey

References (53)

1. Naylor KL, McArthur E, Leslie WD et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int 2014; 86: 810-818
2. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366
3. Tentori F, McCullough K, Kilpatrick RD et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 2014; 85: 166-173
4. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012; 8: 529-543
5. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33: 747-783
6. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19: 179-192
7. Ryan ZC, Ketha H, McNulty MS et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 2013; 110: 6199-6204
8. Kramer I, Loots GG, Studer A et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010; 25: 178-189
9. Fujita K, Roforth MM, Demaray S et al. Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab 2014; 99: E81-E88
10. Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230
11. Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823
12. Goncalves FL, Elias RM, dos Reis LM et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 2014; 15: 190
13. De Oliveira RA, Barreto FC, Mendes M et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int 2014; 87: 1039-1045
14. Baek K, Hwang HR, Park HJ et al. TNF-alpha upregulates sclerostin expression in obese mice fed a high-fat diet. J Cell Physiol 2014; 229: 640-650
15. Poole KE, Van Bezooijen RL, Loveridge N et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842-1844
16. Modder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373-379
17. Zhu D, Mackenzie NC, Millan JL et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6: e19595
18. Koos R, Brandenburg V, Mahnken AH et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 2013; 22: 317-325
19. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011; 109: 564-577
20. Cheng SL, Shao JS, Behrmann A et al. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 1679-1689
21. Martinez-Moreno JM, Munoz-Castaneda JR, Herencia C et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/betacatenin activation. Am J Physiol Renal Physiol 2012; 303: F1136-F1144
22. Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128
23. Claes KJ, Viaene L, Heye S et al. Sclerostin: another vascular calcification inhibitor?. J Clin Endocrinol Metab 2013; 98: 3221-3228
24. Al-Aly Z, Shao JS, Lai CF et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-a-dependent signals in diabetic Ldlr - / - mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-2596
25. Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-1220
26. Beazley KE, Deasey S, Lima F et al. Transglutaminase 2-mediated activation of beta-catenin signaling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol 2012; 32: 123-130
27. Kanbay M, Siriopol D, Saglam M et al. Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-E1861
28. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
29. Cejka D, Marculescu R, Kozakowski N et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248-255
30. Delanaye P, Krzesinski JM, Warling X et al. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 2014; 128: 127-134
31. Ishimura E, Okuno S, Ichii M et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014; 99: 4315-4320
32. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
33. Sabbagh Y, Graciolli FG, O'Brien S et al. Repression of osteocyte Wnt/betacatenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772
34. De Oliveira RB, Graciolli FG, dos Reis LM et al. Disturbances of Wnt/ beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant 2013; 28: 2510-2517
35. Ferreira JC, Ferrari GO, Neves KR et al Effects of Dietary Phosphate on Adynamic Bone Disease in Rats with Chronic Kidney Disease-role of Sclerostin?. PLoS One 2013; 8: e79721
36. Register TC, Hruska KA, Divers J et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab 2014; 99: 315-321
37. Roforth MM, Fujita K, McGregor UI et al. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 2014; 59: 1-6
38. Bonani M, Rodriguez D, Fehr T et al. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 2014; 39: 230-239
39. Viaene L, Behets GJ, Claes K et al Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis?. Nephrol Dial Transplant 2013; 28: 3024-3030
40. Drechsler C, Evenepoel P, Vervloet MG et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2014; 30: 288-293
41. Ardawi MS, Al-Sibiany AM, Bakhsh TM et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int 2012; 23: 1789-1797
42. Szulc P, Boutroy S, Vilayphiou N et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res 2013; 28: 1760-1770
43. Brandenburg VM, Kramann R, Koos R et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 2013; 14: 219
44. Hampson G, Edwards S, Conroy S et al. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013; 56: 42-47
45. Register TC, Hruska KA, Divers J et al. Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2013; 98: E60-E65
46. Szulc P, Schoppet M, Rachner TD et al. Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. J Clin Endocrinol Metab 2014; 99: 617-624
47. Fang Y, Ginsberg C, Seifert M et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014; 25: 1760-1773
48. Lindberg K, Olauson H, Amin R et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8: e60658
49. Chow JT, Khosla S, Melton LJ III et al. Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res 2008; 23: 1601-1612
50. Adragao T, Herberth J, Monier-Faugere MC et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 450-455
51. Moe SM, Chen NX, Newman CL et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 2014; 30: 499-509
52. McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-420
53. Clarke BL, Drake MT. Clinical utility of serum sclerostin measurements. Bonekey Rep 2013; 2: 361